Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer

Dehn, Hannah; Høgdall, Estrid; Johansen, Julia S.; Jørgensen, Morten; Price, P. A.; Engelholm, Svend Aage; Høgdall, Claus

doi:10.1080/j.1600-0412.2003.00010.x

Cited by 14 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the biomarkers identified, CHI3L1 has been most widely studied as an EOC biomarker and it was first postulated as an early‐stage EOC biomarker a decade ago . In our study, CHI3L1 was expressed in the majority of EOC cases, with 66% of early‐stage tumours showing moderate or strong expression.…”

Section: Discussionsupporting

confidence: 48%

“…CHI3L1 is a secreted glycoprotein that can be detected in the blood, and in EOC patients plasma levels of CHI3L1 positively correlate with tumour grade and previous studies find that CHI3L1 appears to offer no advantage over CA125 as a screening biomarker for detection of early‐stage EOC . In our study, CHI3L1 was strongly associated with a poorer prognosis, and high serum CHI3L1 is reportedly an independent negative prognostic factor in EOC patients, so while CHI3L1 is unlikely to be a useful diagnostic biomarker, it may be a useful prognostic tool.…”

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three‐dimensional genetic models of ovarian carcinogenesis

Lawrenson

Mhawech‐Fauceglia

Worthington

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is still considered the most lethal gynecological malignancy and improved early detection of ovarian cancer is crucial to improving patient prognoses. To address this need, we tested whether candidate EOC biomarkers can be identified using three-dimensional (3D) in vitro models. We quantified changes in the abundance of secreted proteins in a 3D genetic model of early-stage EOC, generated by expressing CMYC and KRAS G12V in TERT-immortalized normal ovarian epithelial cells. Cellular proteins were labeled in live cells using stable isotopic amino acid analogues, and secreted proteins identified and quantified using liquid chromatography-tandem mass spectrometry. Thirty-seven and 55 proteins were differentially expressed by CMYC and CMYC1KRAS G12V expressing cells respectively (p < 0.05; >2-fold). We evaluated expression of the top candidate biomarkers in~210 primary EOCs: CHI3L1 and FKBP4 are both expressed by >96% of primary EOCs, and FASN and API5 are expressed by 86 and 75% of cases. High expression of CHI3L1 and FKBP4 was associated with worse patient survival (p 5 0.042 and p 5 0.002, respectively). Expression of LGALS3BP was positively associated with recurrence (p 5 0.0001) and suboptimal debulking (p 5 0.018) suggesting that these proteins may be novel prognostic biomarkers. Furthermore, within early stage tumours (I/II), high expression of API5, CHI3L1 and FASN was associated with high tumour grade (p 5 3 3 10 24 , p 5 0.016, p 5 0.010, respectively). We show in vitro cell biology models of early-stage cancer development can be used to identify novel candidate biomarkers for disease, and report the identification of proteins that represent novel potential candidate diagnostic and prognostic biomarkers for this highly lethal disease.Despite recent advances in surgery and chemotherapy, epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy, mainly due to the absence of specific symptoms and a lack of effective screening tools. The majority of patients present with advanced stage disease where the 5-year survival rate is only 27%. For advanced stage tumours, recurrence rates are over 60%, and 20% of these patients respond poorly to platinum-based chemotherapy. Therefore, detecting patients with early EOC continues to be an urgent clinical need and it remains a clinical priority to detect highgrade serous EOC early during disease development.Given the difficulties accessing the ovary for biopsy and the rapid rate at which the most aggressive EOC subtypes progress, the identification of clinical biomarkers detectable in the blood would represent a significant advance for the identification of patients with EOC. Currently the most widely used ovarian cancer biomarker is serum CA125, and this marker is particularly good at detecting disease recurrence. A second marker, HE4, was approved in 2009 for monitoring ovarian cancer progression, and can be elevated

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 57%

Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three‐dimensional genetic models of ovarian carcinogenesis

Lawrenson

Mhawech‐Fauceglia

Worthington

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The usefulness of YKL-40 in the management of recurrent ovarian cancer has been reported. Patients with high plasma YKL-40 at the time of relapse had significantly shorter survival rates than patients with normal levels the plasma YKL-40 was shown to be an independent prognostic factor [11]. Therefore, an elevated preoperative level of serum YKL-40 may be a novel marker for the detection of endometrial cancer, and identify a high risk subset of patients at risk for poor clinical outcomes.…”

Section: Discussionmentioning

confidence: 98%

Immunohistochemical expression of YKL-40 in peritoneal endometriosis

Kim¹,

Hong²,

Park

et al. 2009

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…The relatively new technology of microarray analysis [28,29] may offer further insight into new molecular prognostic markers/therapeutic targets, as it is becoming clear that this is the next evolutionary leap in cancer treatment. YKL-40 holds great promise in this regard; this assertion is supported by the finding that elevated levels of this protein are associated with poor outcome in women with invasive breast cancer [11,12,14] and ovarian cancer [15]. Heretofore, these studies have been mainly done with ELISA of patient sera.…”

Section: Introductionmentioning

confidence: 99%